Arcus Biosciences (RCUS) News Today $11.06 +0.32 (+2.98%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$11.26 +0.20 (+1.76%) As of 02/21/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Q1 Earnings Forecast for RCUS Issued By HC WainwrightFebruary 22 at 2:18 AM | americanbankingnews.comWhat is Wedbush's Forecast for RCUS FY2029 Earnings?Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Wedbush issued their FY2029 EPS estimates for Arcus Biosciences in a report released on Tuesday, February 18th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of $3.03 per share for the year. Wedbush currently has a "February 21 at 7:04 AM | marketbeat.comWhat is HC Wainwright's Estimate for RCUS Q1 Earnings?Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst E. Bodnar anticipates that the company will eaFebruary 21 at 5:56 AM | marketbeat.comThese Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS ForecastsFebruary 20 at 11:05 AM | finance.yahoo.comBank of America Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $17.00Bank of America reduced their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday.February 20 at 8:05 AM | marketbeat.comMorgan Stanley Issues Pessimistic Forecast for Arcus Biosciences (NYSE:RCUS) Stock PriceFebruary 20 at 2:56 AM | americanbankingnews.comArcus Biosciences Completes Stock Offering, Raises Approximately $141.6 MillionFebruary 20 at 2:03 AM | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low After Analyst DowngradeFebruary 20 at 1:21 AM | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Sees Unusually-High Trading Volume - What's Next?Arcus Biosciences (NYSE:RCUS) Sees Unusually-High Trading Volume - Still a Buy?February 19 at 10:14 PM | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of "Buy" by BrokeragesArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned a consensus recommendation of "Buy" from the nine research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommFebruary 19 at 8:20 PM | marketbeat.comMorgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $25.00Morgan Stanley reduced their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday.February 19 at 4:09 PM | marketbeat.comHC Wainwright Has Lowered Expectations for Arcus Biosciences (NYSE:RCUS) Stock PriceHC Wainwright reduced their price objective on shares of Arcus Biosciences from $20.00 to $18.00 and set a "neutral" rating on the stock in a report on Tuesday.February 19 at 4:09 PM | marketbeat.comArcus Biosciences price target lowered to $17 from $22 at BofAFebruary 19 at 9:38 AM | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for Arcus Biosciences (NYSE:RCUS) Stock PriceFebruary 19 at 3:08 AM | americanbankingnews.comArcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst DowngradeArcus Biosciences (NYSE:RCUS) Hits New 1-Year Low Following Analyst DowngradeFebruary 19 at 1:28 AM | marketbeat.comArcus Biosciences falls -14.8%February 18, 2025 | markets.businessinsider.comArcus Biosciences Shares Hit 52-Week Low After $150M Stock OfferingFebruary 18, 2025 | marketwatch.comArcus Biosciences price target lowered to $18 from $20 at H.C. WainwrightFebruary 18, 2025 | markets.businessinsider.comGilead opts out of deal for Arcus cancer therapyFebruary 18, 2025 | msn.com2RCUS : Arcus Biosciences Shares Are Down Today: What's Going On?February 18, 2025 | benzinga.comArcus Biosciences stock dips after pricing $150M offeringFebruary 18, 2025 | msn.comArcus Biosciences prices 13.6M shares at $11.00 in underwritten offeringFebruary 18, 2025 | markets.businessinsider.comArcus Biosciences price target lowered to $25 from $36 at Morgan StanleyFebruary 18, 2025 | markets.businessinsider.comArcus Biosciences, Inc. Announces Underwritten Offering of Common StockFebruary 18, 2025 | businesswire.comArcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock OfferingFebruary 18, 2025 | businesswire.comArcus says new data demonstrated ‘best-in-class potential’ for casdatifanFebruary 17, 2025 | markets.businessinsider.comArcus Biosciences presents new data for casdatifanFebruary 17, 2025 | markets.businessinsider.comNew Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients ...February 15, 2025 | gurufocus.comNew Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney CancerFebruary 15, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest UpdateArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,380,000 shares, a decrease of 22.7% from the January 15th total of 8,250,000 shares. Based on an average daily volume of 693,700 shares, the short-interest ratio is presently 9.2 days. Currently, 13.1% of the shares of the company are sold short.February 15, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), Arcus Biosciences (RCUS)February 12, 2025 | markets.businessinsider.comArcus Biosciences (RCUS) Expected to Announce Earnings on WednesdayArcus Biosciences (NYSE:RCUS) will be releasing earnings before the market opens on Wednesday, February 19, Financial Modeling Prep reports.February 12, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsFebruary 11, 2025 | businesswire.comArcus Biosciences stock hits 52-week low at $12.13February 11, 2025 | msn.comArcus Biosciences to present new data from Casdatifan at 2025 ASCOFebruary 11, 2025 | markets.businessinsider.comArcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU SymposiumFebruary 10, 2025 | businesswire.comArcus Biosciences (NYSE:RCUS) Sets New 52-Week Low - Here's What HappenedArcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low - What's Next?February 10, 2025 | marketbeat.comArcus Biosciences appoints new board memberFebruary 6, 2025 | msn.comArcus Biosciences (NYSE:RCUS) Hits New 52-Week Low - What's Next?Arcus Biosciences (NYSE:RCUS) Hits New 12-Month Low - Should You Sell?February 4, 2025 | marketbeat.comArcus Biosciences' SWOT analysis: stock poised for growth amid clinical trialsFebruary 3, 2025 | msn.comArcus Biosciences (NYSE:RCUS) Shares Up 4.1% - Still a Buy?Arcus Biosciences (NYSE:RCUS) Trading Up 4.1% - Time to Buy?February 3, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Vertex Pharmaceuticals (VRTX) and Arcus Biosciences (RCUS)January 31, 2025 | markets.businessinsider.comRelative Strength Alert For Arcus BiosciencesJanuary 30, 2025 | nasdaq.comArcus Biosciences stock hits 52-week low at $12.86January 30, 2025 | msn.comArcus Biosciences (NYSE:RCUS) Hits New 12-Month Low - Time to Sell?Arcus Biosciences (NYSE:RCUS) Sets New 52-Week Low - Time to Sell?January 29, 2025 | marketbeat.comPrecision BioSciences announces board member's retirementJanuary 29, 2025 | msn.comArcus Biosciences Announces New Employment Inducement GrantsJanuary 24, 2025 | gurufocus.comArcus Biosciences Announces New Employment Inducement GrantsJanuary 24, 2025 | businesswire.comArcus Biosciences (NYSE:RCUS) Sets New 12-Month Low - Time to Sell?Arcus Biosciences (NYSE:RCUS) Reaches New 12-Month Low - Here's What HappenedJanuary 23, 2025 | marketbeat.comPrecision Biosciences chief research officer sells $49,274 in stockJanuary 22, 2025 | msn.com Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Media Mentions By Week RCUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.090.60▲Average Medical News Sentiment RCUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼385▲RCUS Articles Average Week Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Krystal Biotech News Today SpringWorks Therapeutics News Today Biohaven News Today Recursion Pharmaceuticals News Today PTC Therapeutics News Today Organon & Co. News Today Ultragenyx Pharmaceutical News Today Alvotech News Today Avidity Biosciences News Today ADMA Biologics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts